Edesa Biotech Inc Stock price
Is Edesa Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Edesa Biotech Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Edesa Biotech Inc forecast:
Analyst Opinions
9 Analysts have issued a Edesa Biotech Inc forecast:
Don't miss a Thing! We will send you all news about Edesa Biotech Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Edesa Biotech Inc Stock News
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.
| Head office | Canada |
| CEO | Dr. Nijhawan |
| Employees | 17 |
| Founded | 2007 |
| Website | www.edesabiotech.com |


